{
  "company_name": "Nidda Healthcare Holding GmbH (Stada)",
  "legal_entity": "Nidda Healthcare Holding GmbH",
  "alternate_names": [
    "Stada",
    "Stada Arzneimittel",
    "Nidda Healthcare"
  ],
  "sector": "Healthcare - Generic Pharma",
  "geography": "Germany",
  "last_updated": "2026-01-21",
  "data_source": "Debtwire",
  "ratings": {
    "moodys": {
      "rating": "NR",
      "outlook": null
    },
    "sp": {
      "rating": "NR",
      "outlook": null
    },
    "note": "Bonds described as HY. Strong market access suggests solid BB-range credit."
  },
  "overview": {
    "business_description": "Healthcare holding company for Stada, a leading German generic pharmaceuticals and branded products company. Stada manufactures and distributes generic drugs, branded generics, and consumer healthcare products across Europe and globally.",
    "business_positives": [
      "Very low distress score of 8 - performing credit",
      "ALL bonds trading ABOVE PAR (100-104)",
      "Strong primary market access - multiple recent issuances",
      "Leading European generics/branded pharma platform",
      "Recurring revenue from established drug portfolio",
      "Recent TLB A&E at E+350bps - tight pricing for HY",
      "Diversified product portfolio and geographic reach"
    ],
    "fatal_flaw": "Private PE-owned with limited transparency. Generics face pricing pressure. May 2026 RCF maturity approaching. Leverage likely elevated from LBO structure.",
    "ownership": "Private - PE-owned (Bain Capital, Cinven consortium). LBO structure.",
    "recent_news": "Priced EUR 2.263bn/GBP 170m TLB A&E at E+350bps/S+450bps (Dec 2025). Issued EUR 1.15bn Sr Secd Notes 2032 (Oct 2025). Strong M&A activity in pharma sector."
  },
  "quick_assessment": {
    "total_debt": null,
    "cash_on_hand": null,
    "revolver_available": 390,
    "debt_due_one_year": null,
    "cffo": null,
    "interest_expense": null,
    "ebitda": null,
    "note": "Limited financial data - private LBO structure"
  },
  "key_ratios": {
    "debt_to_ebitda": null,
    "net_debt_to_ebitda": null,
    "note": "Financial ratios not publicly disclosed"
  },
  "debt_capitalization": [
    {
      "instrument": "EUR 350m Revolving Credit",
      "amount": 390,
      "maturity": "May 2026",
      "coupon": null,
      "price": null,
      "ytw": null,
      "stw": null,
      "rating": null,
      "seniority": "Senior Secured"
    },
    {
      "instrument": "EUR 2.263bn TLB (Dec 2025 A&E)",
      "amount": 2490,
      "maturity": null,
      "coupon": "E+350bps",
      "price": null,
      "ytw": null,
      "stw": null,
      "rating": null,
      "seniority": "Senior Secured"
    },
    {
      "instrument": "GBP 170m TLB (Dec 2025 A&E)",
      "amount": 215,
      "maturity": null,
      "coupon": "S+450bps",
      "price": null,
      "ytw": null,
      "stw": null,
      "rating": null,
      "seniority": "Senior Secured"
    },
    {
      "instrument": "EUR 1bn Sr Secd Notes",
      "amount": 1100,
      "maturity": "2032",
      "coupon": null,
      "price": 100.87,
      "ytw": null,
      "stw": null,
      "rating": null,
      "seniority": "Senior Secured"
    },
    {
      "instrument": "EUR 570m Sr Secd Notes",
      "amount": 627,
      "maturity": "2030",
      "coupon": null,
      "price": 102.97,
      "ytw": null,
      "stw": null,
      "rating": null,
      "seniority": "Senior Secured"
    },
    {
      "instrument": "EUR 650m Sr Secd Notes",
      "amount": 715,
      "maturity": "2030",
      "coupon": null,
      "price": 102.98,
      "ytw": null,
      "stw": null,
      "rating": null,
      "seniority": "Senior Secured"
    },
    {
      "instrument": "EUR 350m Sr Secd Notes",
      "amount": 385,
      "maturity": "2030",
      "coupon": null,
      "price": 103.78,
      "ytw": null,
      "stw": null,
      "rating": null,
      "seniority": "Senior Secured"
    }
  ],
  "maturity_schedule": {
    "year_1": 390,
    "year_2": 0,
    "year_3": 0,
    "year_4": 0,
    "year_5": 1727,
    "thereafter": 3590,
    "note": "May 2026 RCF maturity, bulk of notes 2030-2032"
  },
  "recent_issuance": [
    {
      "date": "Dec 2025",
      "instrument": "EUR 2.263bn + GBP 170m TLB A&E",
      "pricing": "E+350bps / S+450bps"
    },
    {
      "date": "Oct 2025",
      "instrument": "EUR 1.15bn Sr Secd Notes 2032",
      "pricing": "Market"
    },
    {
      "date": "May 2025",
      "instrument": "EUR 1.3bn",
      "pricing": "HY bond"
    },
    {
      "date": "Oct 2024",
      "instrument": "EUR 1.4bn",
      "pricing": "HY bond"
    }
  ],
  "credit_opinion": {
    "recommendation": "OVERWEIGHT",
    "summary": "Nidda/Stada is a strong performing credit with very low distress score (8). All bonds trading above par (100-104) with recent TLB pricing at tight E+350bps - indicating solid BB-range credit quality. Strong primary market access with multiple successful issuances. Stada is a leading European generics platform with established products. Compare favorably to Cheplapharm (distress 28) in same sector - Stada is healthier.",
    "key_risks": [
      "Private PE-owned - limited financial transparency",
      "Generics face ongoing pricing pressure",
      "May 2026 RCF maturity needs addressing",
      "LBO leverage likely elevated",
      "Healthcare regulatory/reimbursement risk",
      "Competition from Asian generics manufacturers"
    ],
    "key_catalysts": [
      "Continued strong market access for refinancing",
      "EBITDA growth from acquisitions",
      "Potential IPO exit for PE sponsors",
      "Further spread tightening",
      "Rating assignment could boost trading"
    ]
  },
  "distress_indicators": {
    "debtwire_distress_score": 8,
    "lifecycle_status": "Performing credit",
    "trading_signals": "All bonds at 100-104 (above par). TLB at E+350bps - tight for HY. Strong market access. Very healthy credit."
  },
  "peer_comparison": {
    "vs_cheplapharm": "Nidda/Stada distress 8 vs Cheplapharm 28 - significantly healthier despite same sector"
  }
}